[go: up one dir, main page]

MX2020009332A - Proceso para la preparacion de elobixibat. - Google Patents

Proceso para la preparacion de elobixibat.

Info

Publication number
MX2020009332A
MX2020009332A MX2020009332A MX2020009332A MX2020009332A MX 2020009332 A MX2020009332 A MX 2020009332A MX 2020009332 A MX2020009332 A MX 2020009332A MX 2020009332 A MX2020009332 A MX 2020009332A MX 2020009332 A MX2020009332 A MX 2020009332A
Authority
MX
Mexico
Prior art keywords
elobixibat
preparation
relates
prepare
out under
Prior art date
Application number
MX2020009332A
Other languages
English (en)
Inventor
Ganapati G Bhat
Johnson M Coutinho
Mikael Dahlström
Michael Lofthagen
Akinori Tatara
Original Assignee
Elobix Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elobix Ab filed Critical Elobix Ab
Publication of MX2020009332A publication Critical patent/MX2020009332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analytical Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de ciertos compuestos de 1,5-benzotiazepina, y en particular a un proceso para la preparación de elobixibat. El proceso se puede llevar a cabo en condiciones suaves y seguras y se puede utilizar para preparar elobixibat a escala industrial. La invención también se refiere a un proceso para la preparación de un monohidrato cristalino de elobixibat.
MX2020009332A 2018-03-09 2019-03-08 Proceso para la preparacion de elobixibat. MX2020009332A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201811008692 2018-03-09
SE1850474 2018-04-23
PCT/SE2019/050208 WO2019172834A1 (en) 2018-03-09 2019-03-08 Process for the preparation of elobixibat

Publications (1)

Publication Number Publication Date
MX2020009332A true MX2020009332A (es) 2020-10-08

Family

ID=65818584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009332A MX2020009332A (es) 2018-03-09 2019-03-08 Proceso para la preparacion de elobixibat.

Country Status (11)

Country Link
EP (1) EP3762370A1 (es)
JP (2) JP7322048B2 (es)
KR (2) KR102637395B1 (es)
CN (1) CN111836804A (es)
AU (1) AU2019232477A1 (es)
BR (1) BR112020017353A2 (es)
CA (1) CA3091338A1 (es)
IL (1) IL276917A (es)
MX (1) MX2020009332A (es)
TW (2) TWI822738B (es)
WO (1) WO2019172834A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815749C (en) 2010-11-04 2019-12-03 Albireo Ab Ibat inhibitors for the treatment of liver diseases
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245448A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
US12344589B2 (en) * 2019-09-09 2025-07-01 Elobix Ab Method for producing a 1,5-benzothiazepin compound
CN114786772B (zh) * 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2021110884A1 (en) * 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
WO2021110887A1 (en) * 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120676A1 (es) * 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
AR120679A1 (es) * 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
WO2022117778A1 (en) * 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20250040737A (ko) * 2022-08-02 2025-03-24 상하이 하오위안 케멕스프레스 컴퍼니, 리미티드 엘로빅시바트의 결정형 ii 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
TW200708512A (en) 2005-04-07 2007-03-01 Teijin Pharma Ltd Crystal of aminopyrrolidine derivative and production method thereof
WO2009130706A1 (en) 2008-04-21 2009-10-29 Biocon Limited A process for isolation and purification of geldanamycin
CA2815749C (en) 2010-11-04 2019-12-03 Albireo Ab Ibat inhibitors for the treatment of liver diseases
JO3301B1 (ar) * 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106573033A (zh) 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat

Also Published As

Publication number Publication date
KR102740080B1 (ko) 2024-12-06
EP3762370A1 (en) 2021-01-13
JP2021515023A (ja) 2021-06-17
TW202003480A (zh) 2020-01-16
CA3091338A1 (en) 2019-09-12
JP7605901B2 (ja) 2024-12-24
KR20230159639A (ko) 2023-11-21
JP2023109894A (ja) 2023-08-08
IL276917A (en) 2020-10-29
TWI822738B (zh) 2023-11-21
JP7322048B2 (ja) 2023-08-07
WO2019172834A1 (en) 2019-09-12
AU2019232477A1 (en) 2020-09-10
TW202302546A (zh) 2023-01-16
CN111836804A (zh) 2020-10-27
TWI823573B (zh) 2023-11-21
KR102637395B1 (ko) 2024-02-15
KR20200130390A (ko) 2020-11-18
BR112020017353A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
MX2020009332A (es) Proceso para la preparacion de elobixibat.
SA519402400B1 (ar) تركيبات وطرق لعلاج أمراض الهيموجلوبين
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
WO2020225215A3 (de) Verfahren und vorrichtung zur oberflächenbearbeitung
MY199348A (en) Process for preparing optically active 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
NZ739876A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
NZ760847A (en) Purified 2,5-furandicarboxylic acid pathway products
MX2017003518A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MY192571A (en) Treatment installation and method for treating workpieces
MY176401A (en) Novel disubstituted 1,2,4-triazine compound
SG10201804026WA (en) Inhibitors of influenza viruses replication
MX2020009840A (es) Granulos que comprenden l-aminoacido y procedimiento de preparacion de los mismos.
PH12021550028A1 (en) Substituted thiophenecarboxamides and analogues as antibacterials agents
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
IL290973A (en) An industrial process for the preparation of estradiol with a high degree of purity
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
PL3765242T3 (pl) Narzędzie do wspomagania procesu znakowania lub cięcia
MA47511A (fr) Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants
MX378363B (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
WO2015195950A8 (en) Lmp7 inhibitors
PH12019500822A1 (en) Crystalline forms of eravacycline
PH12016502568B1 (en) Novel heterocyclic compound
MX2017009597A (es) Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100.
PT3921257T (pt) Instalação para o tratamento de carroçarias
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine